Ranked as the #1 PBPK software for In Vitro-In Vivo Extrapolation (IVIVE) & PBPK modeling by Pfizer!
GP PDPlus™ Module Flyer
Automated model selection – fit across all direct, indirect, phase-nonspecific cell killing, bacteria killing PD models with a single mouse click to extend your PBPK models in GastroPlus® and easily find relationships between the pharmacodynamics and pharmacokinetics of your compound using plasma and/or tissue concentration profiles!
December 2023 GastroPlus Newsletter
GastroPlus® Newsletter December 2023
Novel application of PBBM to justify impact of faster dissolution on safety and pharmacokinetics – a case study and utility in regulatory justifications
Physiologically based biopharmaceutics modelling (PBBM) was recognised as potential approach for biopharmaceutics applications.
The Complexity of Bariatric Patient’s Pharmacotherapy: Sildenafil Biopharmaceutics and Pharmacokinetics before vs. after Gastric Sleeve/Bypass
Postbariatric altered gastrointestinal (GI) anatomy/physiology may significantly harm oral drug absorption and overall bioavailability.
AP Metabolism Module Flyer
Metabolism plays a critical role in the bioavailability of drugs, food additives, agrochemicals, and industrial chemicals.
AP High-throughput Pharmacokinetic (HTPK) Simulation Module Flyer
ADMET Predictor® property prediction and QSAR model-building application
AP AI-Driven Drug Design (AIDD) Module Flyer
Drug Design... Meet PBPK!
AP ADMET Modeler™ Module Flyer
ADMET Modeler is a QSAR/QSPR model building module in ADMET Predictor®.
AP Toxicity Module Flyer
Every early compound candidate screening tool should neglect toxicity aspects.
Vision, Mission and Values
To improve health through innovative solutions.
AP Physicochemical & Biopharmaceutical (PCB) Module Flyer
ADMET Predictor® property prediction and QSAR model-building application
AP MedChem Studio™ Module Flyer
MedChem Studio is now free of charge for all our users for extended data analysis capabilities.
DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc
New drugs for visceral leishmaniasis that are safe, low cost, and adapted to the field are urgently required.
Evaluating the Role of N-Acetyl-L-Tryptophan in the Aβ 1-42-Induced Neuroinflammation and Cognitive Decline in Alzheimer’s Disease
Alzheimer’s disease (https://www.simulations-plus.com/wp-admin/post.php?post=35654&action=editAD), a neurodegenerative condition previously known to affect the older population, is also now seen in younger individuals.
Creating Quality by Committing to Compliance in Clinical Research
In the highly regulated world of clinical research, compliance is an ongoing concern, but can be viewed as an annoying and costly item to check off a regulatory to-do list.
Physiologically Based Pharmacokinetic Modeling in Neonates: Current Status and Future Perspectives
Rational drug use in special populations is a clinical problem that doctors and pharma-cists must consider seriously.
Log D7.4 and plasma protein binding of synthetic cannabinoid receptor agonists and a comparison of experimental and predicted lipophilicity
The emergence of new synthetic cannabinoid receptor agonists (SCRAs) onto the illicit drugs market continues to cause harm, and the overall availability of physicochemical and pharmacokinetic data for new psychoactive substances is lacking.
QSP Ulcerative Colitis (UC) Model Flyer
Quantitative Systems Pharmacology (QSP)
Ulcerative Colitis Model
QSP Systemic Lupus Erythematosus (SLE) Model Flyer
Quantitative Systems Pharmacology (QSP)
Systemic Lupus Erythematosus Model